Business Wire·Feb 27, 2026, 8:00 AM ET

New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

OGN

Organon will present sub-analysis data from Phase 3 ADORING 1 & 2 trials at the 2026 AAAAI Annual Meeting in Philadelphia on February 27, 2026.
VTAMA cream demonstrated clinically meaningful improvements in sleep scores as early as week 1, sustained through week 8.
Significant improvements in the Patient-Oriented Eczema Measure (POEM) sleep subdomain were observed in pediatric patients aged 2-17 years with moderate to severe atopic dermatitis.
Significant improvements in the Dermatitis Family Impact (DFI) sleep subdomain were observed in family members of patients aged 2-15 years.
POEM sleep scores improved significantly by week 1 for children aged 2-6 and 12-17, with improvements for children aged 7-11 observed by week 4.
At week 8, mean changes in POEM sleep scores favored VTAMA cream over vehicle across all age groups (2-6, 7-11, 12-17) with statistically significant P-values.
DFI sleep scores improved significantly by week 1 for patients aged 12-15, and by week 2 for children aged 2-6 and 7-11.
Clinically significant DFI improvements continued through week 8 across pediatric age groups aged 2-15.
The most frequently reported treatment-emergent adverse events (≥5%) were folliculitis, headache, and nasopharyngitis.
VTAMA cream received FDA approval in December 2024 for topical treatment of atopic dermatitis in adults and pediatric patients aged 2 years and older.
VTAMA cream was previously approved by the FDA in May 2022 for topical treatment of plaque psoriasis in adults.
The ADORING program included two 8-week pivotal trials (ADORING 1 2) and a 48-week open-label extension trial (ADORING 3).